R&D/ Views & Analysis/ Views and analysis Is cardiovascular disease a ‘pandemic hiding in plain sight’? George Underwood Amarin, cardiovascular disease, COVID-19, CVD 0 Comment Amarin’s Craig Granowitz discusses the impact of COVID on cardiovascular disease treatment and explains why there’s still a Share X Is cardiovascular disease a ‘pandemic hiding in plain sight’? https://pharmaphorum.com/views-and-analysis/is-cardiovascular-disease-a-pandemic-hiding-in-plain-sight/
News NICE suggests lower threshold for hypertension treatment Richard Staines cardiology, CVD, NICE 0 Comment Thousands more patients could benefit from drugs and treatment for hypertension under new guidance from NICE, which has Share X NICE suggests lower threshold for hypertension treatment https://pharmaphorum.com/news/nice-suggests-lower-threshold-for-hypertension-treatment-embargo/
News/ News/ R&D Novartis licenses lipoprotein-lowering CVD drug George Underwood Akcea, cardiovascular, CVD, Ionis, Novartis 0 Comment Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment Share X Novartis licenses lipoprotein-lowering CVD drug https://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/
